InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of 21.05 million. The enterprise value is 18.01 million.
| Market Cap | 21.05M |
| Enterprise Value | 18.01M |
Important Dates
The next estimated earnings date is Tuesday, March 31, 2026.
| Earnings Date | Mar 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 4.50M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +5.42% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 3.41% |
| Owned by Institutions (%) | n/a |
| Float | 3.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.78 |
| PB Ratio | 3.17 |
| P/TBV Ratio | 5.46 |
| P/FCF Ratio | 37.73 |
| P/OCF Ratio | 36.81 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.57 |
| EV / Sales | 0.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 32.28 |
Financial Position
The company has a current ratio of 3.72, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.72 |
| Quick Ratio | 2.72 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.73 |
| Interest Coverage | -313.00 |
Financial Efficiency
Return on equity (ROE) is -33.07% and return on invested capital (ROIC) is -145.92%.
| Return on Equity (ROE) | -33.07% |
| Return on Assets (ROA) | -7.56% |
| Return on Invested Capital (ROIC) | -145.92% |
| Return on Capital Employed (ROCE) | -15.35% |
| Weighted Average Cost of Capital (WACC) | 4.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 5 |
| Asset Turnover | 2.61 |
| Inventory Turnover | 1.06 |
Taxes
In the past 12 months, InnoCan Pharma has paid 739,000 in taxes.
| Income Tax | 739,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.62% in the last 52 weeks. The beta is 0.02, so InnoCan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -39.62% |
| 50-Day Moving Average | 8.84 |
| 200-Day Moving Average | 21.34 |
| Relative Strength Index (RSI) | 37.13 |
| Average Volume (20 Days) | 1,228 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 27.03 million and -3.23 million in losses. Loss per share was -0.72.
| Revenue | 27.03M |
| Gross Profit | 23.91M |
| Operating Income | -1.25M |
| Pretax Income | -1.51M |
| Net Income | -3.23M |
| EBITDA | -1.22M |
| EBIT | -1.25M |
| Loss Per Share | -0.72 |
Balance Sheet
The company has 7.27 million in cash and 1.52 million in debt, with a net cash position of 5.75 million.
| Cash & Cash Equivalents | 7.27M |
| Total Debt | 1.52M |
| Net Cash | 5.75M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.63M |
| Book Value Per Share | 0.86 |
| Working Capital | 8.06M |
Cash Flow
In the last 12 months, operating cash flow was 572,000 and capital expenditures -14,000, giving a free cash flow of 558,000.
| Operating Cash Flow | 572,000 |
| Capital Expenditures | -14,000 |
| Free Cash Flow | 558,000 |
| FCF Per Share | n/a |
Margins
Gross margin is 88.47%, with operating and profit margins of -4.63% and -11.96%.
| Gross Margin | 88.47% |
| Operating Margin | -4.63% |
| Pretax Margin | -5.57% |
| Profit Margin | -11.96% |
| EBITDA Margin | -4.50% |
| EBIT Margin | -4.63% |
| FCF Margin | 2.06% |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.42% |
| Shareholder Yield | -5.42% |
| Earnings Yield | -15.36% |
| FCF Yield | 2.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 5, 2025. It was a reverse split with a ratio of 0.0153846.
| Last Split Date | Sep 5, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.0153846 |
Scores
InnoCan Pharma has an Altman Z-Score of 3.7 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.7 |
| Piotroski F-Score | 3 |